Pfizer-BioNTech vaccine sharply reduces symptomatic Covid-19 in the real world, Israeli researchers say
February 15, 2021. Summarized by summa-bot.
Compression ratio: 64.1%. 1 min read.
A nurse handles a vial of the the Pfizer-BioNTech Covid-19 vaccine at the Wolfson medical center in Holon, Israel, on Sunday, Dec. 20, 2020. Israelis returning from the U.K., Denmark, and South Africa will be sent to isolation in government-run quarantine sites to help prevent a mutant strain of coronavirus from entering the country. Photographer: Kobi Wolf/Bloomberg
Pfizer-BioNTech's Covid-19 vaccine appears to reduce symptomatic coronavirus infections by more than 90% in the real world, Israeli researchers said Sunday.
(CNN)Pfizer-BioNTech's Covid-19 vaccine appears to reduce symptomatic coronavirus infections by more than 90% in the real world, Israeli researchers said Sunday.
The Clalit Research Institute, part of a large Israeli health system, analyzed data on 1. 2 million people, about half of whom had received the Pfizer-BioNTech vaccine.
Researchers compared patients who received the vaccine with similar individuals who hadn't.
The rate of symptomatic Covid-19 -- meaning people who were infected with the coronavirus and felt sick -- decreased by 94% among people who received two doses of the vaccine, according to a press release from Clalit.
Still, the findings are consistent with data from Pfizer's own vaccine trial, which found that the vaccine conferred 95% protection against symptomatic Covid-19.
In the Pfizer trial, researchers randomly assigned patients to receive either the vaccine or a placebo.
Pfizer's study was a randomized controlled trial, the gold standard in clinical research.
The Israeli study, on the other hand, was observational, meaning researchers didn't randomly pick who got the vaccine and who didn't.
And observational studies are important because they can offer certain insight into how well vaccines protect people under real-world conditions.